TAGline Spring 2018
16 April 2018. Related: On the web.
2018
16 April 2018: vol 19 no 7
16 April 2018. Related: PDFs.
30 March 2018: vol 19 no 6 – CROI 2018 part 2
30 March 2018. Related: Editorial.
CROI 2018: second reports
30 March 2018. Related: Conference reports.
Ibalizumab 24-week phase 3 results and susceptibility to drug-resistant HIV
30 March 2018. Related: Conference reports, Antiretrovirals.
Statin use might reduce risk of cancer in HIV positive people
30 March 2018. Related: Conference reports, Cancer and HIV.
Rate of bone loss on ART slows after the first year
30 March 2018. Related: Conference reports, Side effects.
Standard dose of dolutegravir sufficient in late pregnancy: interim results from DolPHIN-1 study
30 March 2018. Related: Conference reports, Pregnancy.
Women’s risk of becoming HIV positive increases three-fold in late pregnancy and four-fold postpartum
30 March 2018. Related: Conference reports.
Cure research at CROI 2018: defining and reducing the reservoir and the risks from interrupting treatment
30 March 2018. Related: Conference reports, Cure-related research.
Elite controllers: sex differences and factors associated with loss of immune control
30 March 2018. Related: Cure-related research, Basic science and immunology.
Assessing antiretroviral therapy interruptions in HIV cure research
30 March 2018. Related: Cure-related research.
Update on PrEP IMPACT study (March 2018)
30 March 2018. Related: HIV prevention and transmission.
US Congress rejects Trump’s proposed cuts to research budget for 2018
30 March 2018. Related: Other news.
HCV advocacy training manual
30 March 2018. Related: On the web.
30 March 2018: vol 19 no 6
30 March 2018. Related: PDFs.
14 March 2018: vol 19 no 5 – CROI 2018 part 1
14 March 2018. Related: Editorial.
25th Conference on Retroviruses and Opportunistic Infections (CROI 2018)
14 March 2018. Related: Conference reports.
Inching towards an HIV cure: bNAb and TLR-7 agonist reduce viral rebound off-ART in macaques
14 March 2018. Related: Conference reports, Cure-related research.
No HIV evolution in plasma or lymph nodes on suppressive ART and no impact from further intensification
14 March 2018. Related: Conference reports, Cure-related research.
Dual therapy can reduce TB prophylaxis from nine months to one: fewer side effects and more people complete treatment
14 March 2018. Related: Conference reports, TB coinfection.
Twice-daily dolutegravir is effective and tolerable with rifampicin
14 March 2018. Related: Conference reports, PK and drug interactions, TB coinfection.
Once-daily tenofovir alafenamide appears sufficient when dosed with rifampicin
14 March 2018. Related: Conference reports, TB coinfection.
Efavirenz 400 mg can be given with anti-tuberculosis treatment
14 March 2018. Related: Conference reports, TB coinfection.
Bictegravir at CROI 2018: switching studies and drug resistance analyses
14 March 2018. Related: Conference reports, Antiretrovirals, Drug resistance.
PrEP at CROI 2018 (part 1): Access in Australia and the US
14 March 2018. Related: Conference reports, HIV prevention and transmission.
PrEP at CROI 2018 (part 2): Animal studies for future drugs
14 March 2018. Related: Conference reports, HIV prevention and transmission.
BHIVA best of CROI feedback workshops
14 March 2018. Related: Conference reports.
FDA approves ibalizumab in the US to treat multidrug HIV resistance
14 March 2018. Related: Antiretrovirals.
14 March 2018: vol 19 no 5
14 March 2018. Related: PDFs.
23 February 2018: vol 19 no 4
23 February 2018. Related: PDFs.
23 February 2018: vol 19 no 4
23 February 2018. Related: Editorial.
CROI 2018 – highlights from the preliminary programme
23 February 2018. Related: Conference reports.
FDA grants tentative approval to first DTG/FTC/TAF FDC
23 February 2018. Related: Antiretrovirals, Treatment access.
Universal ART on diagnosis: approved by NHS England
23 February 2018. Related: Treatment access.
Standard once-daily dolutegravir dosing achieves target levels during pregnancy
23 February 2018. Related: Pregnancy.
Meta-analysis reports no significant risk of cardiac, IRIS or suicide with dolutegravir
23 February 2018. Related: Side effects.
Significant drug-drug interaction between dolutegravir and isoniazid-rifapentine
23 February 2018. Related: PK and drug interactions.
New data on identifying and targeting the latent HIV reservoir
23 February 2018. Related: Cure-related research.
Recruiting natural killer cells to target HIV persistence
23 February 2018. Related: Cure-related research.
Discrimination against gay men overturned with new HPV vaccine programme for England
23 February 2018. Related: Other news.
UK study highlights discrimination against trans people living with HIV
23 February 2018. Related: Other news.
PrEP resources for access
23 February 2018. Related: On the web.
09 February 2018: vol 19 no 3
9 February 2018. Related: Editorial.
Bictegravir approved in the US in new integrase-inhibitor based FDC (Biktarvy)
9 February 2018. Related: Antiretrovirals.
US approve a lower-dose efavirenz (400 mg) based generic FDC (Simfi Lo)
9 February 2018. Related: Antiretrovirals.
ViiV announces phase 3 study switching to dolutegravir/3TC dual therapy from TAF-containing ART
9 February 2018. Related: Antiretrovirals, Research studies.
US darunavir label updated: drug interactions and pregnancy
9 February 2018. Related: Antiretrovirals.
75% of WHO essential medicines could be cheaper: UK and South Africa both overpay
9 February 2018. Related: Treatment access.
New HIV pregnancy study uses latest ART: IMPAACT 2010 study (VESTED) includes dolutegravir and tenofovir alafenamide (TAF)
9 February 2018. Related: Pregnancy.
Association between timing of maternal ART and risk of infants born small for gestational age in Dutch ATHENA cohort
9 February 2018. Related: Pregnancy.
London clinic to prescribe generic PrEP privately at £55 for 30 tablets
9 February 2018. Related: Treatment access, HIV prevention and transmission.
BHIVA standards of HIV care (2018): online for comment
9 February 2018. Related: Guidelines.
UK HIV pregnancy guidelines (2018): online for comment
9 February 2018. Related: Guidelines.
HIV conversations in the UK
9 February 2018. Related: On the web.
Women in Science: IAS feature
9 February 2018. Related: On the web.
Yale CRIT conference: blogs on the threats from changes to drug regulation in the US and Europe
9 February 2018. Related: On the web.
09 February 2018: vol 19 no 3
9 February 2018. Related: PDFs.
22 January 2018: vol 19 no 2
22 January 2018. Related: Editorial.
HIV in the UK 2017: a shift to eliminate AIDS
22 January 2018. Related: Special reports, HIV prevention and transmission.
Doravirine FDC submitted to FDA in US: decision expected October 2018
22 January 2018. Related: Antiretrovirals.
Update on PrEP IMPACT study – January 2018
22 January 2018. Related: HIV prevention and transmission.
PrEP use can reduce HIV stigma in gay communities
22 January 2018. Related: HIV prevention and transmission.
European HIV/AIDS surveillance report published (2017)
22 January 2018. Related: HIV prevention and transmission.
Additional remission cases published: but eradication needs 10,000-fold reduction in viral reservoir
22 January 2018. Related: Cure-related research.